Bright Minds to report Phase 2 epilepsy trial results on Tuesday

Bright Minds will host a conference call and webcast Tuesday at 8:00 AM ET to announce topline results from its Phase 2 trial of BMB-101 in drug-resistant absence seizures and developmental and epileptic encephalopathy.

Bright Minds Biosciences will hold a conference call and webcast on Tuesday at 8:00 AM ET to announce topline results from its Phase 2 study of BMB-101. The trial involves patients with drug-resistant absence seizures and developmental and epileptic encephalopathy. The company develops selective 5-HT receptor agonists for neurological and psychiatric disorders. Recent analyst commentary and market moves have drawn attention to the timing of these data. Key details: - The article reports the call and webcast are scheduled for Tuesday at 8:00 AM ET to present topline Phase 2 results for BMB-101 in drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. - The virtual event will be accessible through the Investors section of the company’s website, and a replay will be available after the presentation. - The article notes Bright Minds focuses on developing selective serotonergic (5-HT) agonists targeting conditions with high unmet medical needs. - According to InvestingPro data cited in the article, the company’s shares have risen nearly 195% over the past six months and the market capitalization is reported as approximately $656 million. - The article says H.C. Wainwright reiterated a Buy rating with a $115 price target and Cantor Fitzgerald maintained an Overweight rating, and that TD Cowen highlighted the company as a biotech with catalysts to watch in 2026. - The article reports Bright Minds added four experts to its Scientific Advisory Board to support a Prader‑Willi Syndrome program and nominated BMB-105 as a new clinical candidate. Summary: The company will present topline Phase 2 data for BMB-101 at a scheduled webcast on Tuesday morning, with a replay to be posted on its investor site. The article reports recent analyst coverage and notable share-price movement as context for market interest. The immediate next step is the live presentation and question-and-answer session; further development or regulatory steps were not detailed.